This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kageshita, T. Articles by Ferrone, S. Search for Related Content PubMed PubMed Citation Articles by Kageshita, T. Articles by Ferrone, S.

Association of High Molecular Weight Melanoma-associated Antigen Expression in Primary Acral Lentiginous Melanoma Lesions with Poor Prognosis¹

Department of Dermatology, Kumamoto University Medical School, Kumamoto, Japan [T. K., N. K., T. O.]; Department of Dermatology, Sapporo Medical College, Sapporo, Japan [T. H., M. T.]; Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York [G. Y. W.]; and Department of Microbiology and Immunology, New York Medical College, Valhalla, New York [S. F.]

In a recent study we detected marked differences in the antigenic profile of acral lentiginous melanoma (ALM) and nodular melanoma lesions. Furthermore, we showed that the human high molecular weight melanoma-associated antigen (HMW-MAA) is expressed with a significantly higher frequency in metastatic than in primary ALM lesions. Because of the potential role of HMW-MAA in the metastatic process of melanoma cells, in the present investigation we tested whether HMW-MAA represents a useful prognostic marker in ALM. Primary ALM lesions removed from 32 patients were stained with anti-HMW-MAA monoclonal antibody (mAb) in an immunoperoxidase reaction. The results were correlated with the expression of other markers defined by mAb, with clinical parameters of the disease, and with histopathological characteristics of the lesions. Only 9 of the 32 primary ALM lesions tested were stained by anti-HMW-MAA mAb. Expression of HMW-MAA was the only variable associated with patients' survival and disease-free survival. Both were significantly shorter in patients with HMW-MAA expression in their primary lesions. These results suggest that HMW-MAA may represent a novel prognostic marker in ALM, since phenotyping of primary ALM lesions with anti-HMW-MAA mAb may provide information about the prognosis of the disease which cannot be obtained with known prognostic parameters.

¹ This investigation was supported by Public Health Service Grant CA39559 awarded by the National Cancer Institute.

² To whom requests for reprints should be addressed, at Department of Microbiology and Immunology, New York Medical College, Basic Sciences Building, Valhalla, NY 10595.

Received 10/ 1/92. Accepted 4/ 9/93.

This article has been cited by other articles:

				J. L. Murray, M. Gillogly, K. Kawano, C. L. Efferson, J. E. Lee, M. Ross, X. Wang, S. Ferrone, and C. G. Ioannides Fine Specificity of High Molecular Weight-Melanoma-Associated Antigen-Specific Cytotoxic T Lymphocytes Elicited by Anti-Idiotypic Monoclonal Antibodies in Patients with Melanoma Cancer Res., August 1, 2004; 64(15): 5481 - 5488. [Abstract] [Full Text] [PDF]

				J. Yang, M. A. Price, C. L. Neudauer, C. Wilson, S. Ferrone, H. Xia, J. Iida, M. A. Simpson, and J. B. McCarthy Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms J. Cell Biol., June 21, 2004; 165(6): 881 - 891. [Abstract] [Full Text] [PDF]

				F. Martin, S. Neil, J. Kupsch, M. Maurice, F.-L. Cosset, and M. Collins Retrovirus Targeting by Tropism Restriction to Melanoma Cells J. Virol., August 1, 1999; 73(8): 6923 - 6929. [Abstract] [Full Text]